According to IQVIATM, sales data for the 12 month period ending March 2020, the Chlorzoxazone Tablets, 375 mg and 750 mg market achieved annual sales of approximately $20.9 million.
Glenmark's current portfolio consists of 163 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Powered by Capital Market - Live News